疑难病杂志
疑難病雜誌
의난병잡지
JOURNAL OF DIFFICULT AND COMPLICATED CASES
2014年
6期
601-603
,共3页
肝癌%色素上皮衍生因子%血管内皮生长因子%预后%关系
肝癌%色素上皮衍生因子%血管內皮生長因子%預後%關繫
간암%색소상피연생인자%혈관내피생장인자%예후%관계
Hepatocellular carcinoma%Pigment epithelium derived factor%Vascular endothelial growth factor%Progno-sis%Correlation
目的:观察肝癌患者血浆色素上皮衍生因子(PEDF)及血管内皮生长因子(VEGF)表达水平并探讨其与预后的关系。方法采用ELISA法检测肝癌患者43例(肝癌组)、肝脏良性疾病患者20例(良性肝病组)及健康对照者20例(健康对照组)血浆PEDF和VEGF水平;肝癌患者平均随访(12 W.02±0.23)个月,记录短期主要不良终点事件(SMAE)发生情况。结果血浆PEDF水平肝癌组较良性肝病组及健康对照组明显降低( P <0.01),VEGF水平明显升高( P <0.01),而良性肝病组与健康对照组比较差异无统计学意义( P >0.05)。肝癌患者随访结束后,高PEDF/VEGF比值(≥3)亚组22例发生SMAE 3例(13.64%),低PEDF/VEGF比值(<3)亚组21例发生SMAE 7例(33.33%),Kaplan-Meier生存曲线显示2组差异有统计学意义( P =0.039)。另外,与未发生SMAE的肝癌患者(33例)比较,发生SMAE者(10例)有更低的PEDF/VEGF比值(2.14±0.76 vs.3.49±1.12, P <0.01)。结论 PEDF和VEGF参与肝癌的病理生理过程,低表达的PEDF及高表达的VEGF反映肝癌发生、发展及转移情况,两者比值可能成为预测肝癌转移及预后的有效指标。
目的:觀察肝癌患者血漿色素上皮衍生因子(PEDF)及血管內皮生長因子(VEGF)錶達水平併探討其與預後的關繫。方法採用ELISA法檢測肝癌患者43例(肝癌組)、肝髒良性疾病患者20例(良性肝病組)及健康對照者20例(健康對照組)血漿PEDF和VEGF水平;肝癌患者平均隨訪(12 W.02±0.23)箇月,記錄短期主要不良終點事件(SMAE)髮生情況。結果血漿PEDF水平肝癌組較良性肝病組及健康對照組明顯降低( P <0.01),VEGF水平明顯升高( P <0.01),而良性肝病組與健康對照組比較差異無統計學意義( P >0.05)。肝癌患者隨訪結束後,高PEDF/VEGF比值(≥3)亞組22例髮生SMAE 3例(13.64%),低PEDF/VEGF比值(<3)亞組21例髮生SMAE 7例(33.33%),Kaplan-Meier生存麯線顯示2組差異有統計學意義( P =0.039)。另外,與未髮生SMAE的肝癌患者(33例)比較,髮生SMAE者(10例)有更低的PEDF/VEGF比值(2.14±0.76 vs.3.49±1.12, P <0.01)。結論 PEDF和VEGF參與肝癌的病理生理過程,低錶達的PEDF及高錶達的VEGF反映肝癌髮生、髮展及轉移情況,兩者比值可能成為預測肝癌轉移及預後的有效指標。
목적:관찰간암환자혈장색소상피연생인자(PEDF)급혈관내피생장인자(VEGF)표체수평병탐토기여예후적관계。방법채용ELISA법검측간암환자43례(간암조)、간장량성질병환자20례(량성간병조)급건강대조자20례(건강대조조)혈장PEDF화VEGF수평;간암환자평균수방(12 W.02±0.23)개월,기록단기주요불량종점사건(SMAE)발생정황。결과혈장PEDF수평간암조교량성간병조급건강대조조명현강저( P <0.01),VEGF수평명현승고( P <0.01),이량성간병조여건강대조조비교차이무통계학의의( P >0.05)。간암환자수방결속후,고PEDF/VEGF비치(≥3)아조22례발생SMAE 3례(13.64%),저PEDF/VEGF비치(<3)아조21례발생SMAE 7례(33.33%),Kaplan-Meier생존곡선현시2조차이유통계학의의( P =0.039)。령외,여미발생SMAE적간암환자(33례)비교,발생SMAE자(10례)유경저적PEDF/VEGF비치(2.14±0.76 vs.3.49±1.12, P <0.01)。결론 PEDF화VEGF삼여간암적병리생리과정,저표체적PEDF급고표체적VEGF반영간암발생、발전급전이정황,량자비치가능성위예측간암전이급예후적유효지표。
Objective To observe the expression of pigment epithelium derived factor ( PEDF) and vascular endothe-lial growth factor ( VEGF) in liver cancer patients , and to explore its relationship with the prognosis .Methods ELISA was used to detect 43 cases of patients with hepatocellular carcinoma (HCC group), 20 patients with benign liver disease (benign liver disease group ) and 20 cases of healthy controls'( healthy control group ) levels of plasma PEDF and VEGF levels , pa-tients with hepatocellular carcinoma with average follow-up (12.02 ±0.23) months, the main short recording adverse events ( SMAE) occurrence were recorded .Results The levels of plasma PEDF of liver cancer group decreased than in benign liver disease group and healthy control group ( P <0.01), VEGF level increased significantly ( P <0.01), and benign disease group and the healthy control group had no significant difference ( P >0 .05 ) .At the end of the follow-up of patients with hepatocellular carcinoma , high ratio of PEDF/VEGF subgroup (22 cases, PEDF/VEGF≥3) SMAE occurred in 3 patients (13.64%), low PEDF/VEGF ratio subgroup (21 cases, PEDF/VEGF <3) SMAE occurred in 7 patients (33.33%), Ka-plan-Meier survival curve showed statistically significant differences between the 2 groups ( P =0.039).In addition, com-pared with without the occurrence of SMAE in patients with hepatocellular carcinoma (33 cases) , patients with occurrence of SMAE (10 cases) with lower PEDF/VEGF ratio (2.14 ±0.76 vs.3.49 ±1.12, P <0.01).Conclusion PEDF and VEGF have role in the pathophysiology of hepatocellular carcinoma , low expression of PEDF and high expression of VEGF re-flects the development and metastasis of HCC , the ratio between the two may be an effective index to predict the metastasis and prognosis of hepatocellular carcinoma .